Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 17/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 16/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671706 | 1.00 | ITGA4 (0.46) | ITGA4ITGB1CHEK1MEN1MAPT | |
| SCHEMBL6515595 | 1.00 | ITGA4 (0.46) | ITGA4ITGB1CHEK1MEN1MAPT | |
| Hydrochloric Acid SCHEMBL4674500 | 0.99 | ITGA4 (0.45) | ITGA4ITGB1CHEK1MEN1MAPT | |
| Hydrochloric Acid SCHEMBL4674517 | 0.99 | ITGA4 (0.45) | ITGA4ITGB1CHEK1MEN1MAPT | |
| Hydrochloric Acid SCHEMBL4674506 | 0.99 | ITGA4 (0.45) | ITGA4ITGB1CHEK1MEN1MAPT | |
| SCHEMBL14222075 | 0.93 | ITGA4 (0.39) | ITGA4ITGB1CHEK1MEN1MAPT | |
| SCHEMBL6595778 | 0.93 | ITGA4 (0.39) | ITGA4ITGB1CHEK1MEN1MAPT | |
| SCHEMBL4672022 | 0.93 | ITGA4 (0.39) | ITGA4ITGB1CHEK1MEN1MAPT | |
| SCHEMBL8358412 | 0.93 | ITGA4 (0.39) | ITGA4ITGB1CHEK1MEN1MAPT | |
| SCHEMBL4675589 | 0.92 | ITGA4 (0.44) | ITGA4ITGB1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962937-B2 | Imidazolidine derivatives, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1414444-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| WO-2003011288-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | VCAM1, ITGA1, ITGA4 | ITGA4 3/4885ITGB1 5/4885CHEK1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.